文献速递脑血管病

ADRB1基因多态性与小血管卒中后心血管结局的关联:SPS3试验药物遗传学分析

Pharmacogenetic Associations of β1-Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes).
PubMed 文献 · Stroke · 2017-03-28

在SiGN队列中验证了Gly49与小动脉缺血性卒中的关联;β受体阻滞剂治疗可能增加Gly49携带者的MACE风险。

要点

  • ADRB1 Gly49携带者MACE风险升高(HR 1.62,95%CI 1.00-2.68)。
  • Gly49与缺血性卒中相关(HR 1.81,95%CI 1.01-3.23)。
  • β受体阻滞剂治疗的Gly49携带者MACE风险进一步增加(HR 2.03,95%CI 1.20-3.45)。

核心结论

  • 在既往小动脉缺血性卒中患者中,ADRB1 Gly49多态性与MACE相关,尤其与小动脉缺血性卒中相关,且该风险在β受体阻滞剂治疗者中可能增加。

主要发现

  • Gly49携带者MACE发生率为10.5%,Ser49Ser基因型为5.4%(log-rank P=0.005)。
  • SPS3中Gly49携带状态与MACE相关(HR 1.62,95%CI 1.00-2.68),与缺血性卒中相关(HR 1.81,95%CI 1.01-3.23)。
  • SiGN中Gly49与小动脉缺血性卒中相关(OR 1.14,95%CI 1.03-1.26)。
  • SPS3中接受β受体阻滞剂治疗的Gly49携带者MACE风险高于未治疗者及非携带者(HR 2.03,95%CI 1.20-3.45)。
  • 未观察到Arg389Gly多态性与结局的关联。

临床怎么用

  • 对于有小动脉缺血性卒中史的高血压患者,可考虑ADRB1 Gly49基因型检测以评估MACE风险。
  • Gly49携带者使用β受体阻滞剂时需警惕MACE风险增加,个体化权衡获益与风险。

局限性

  • 研究为遗传亚组分析,样本量有限,需进一步研究明确β受体阻滞剂在不同ADRB1基因型缺血性卒中患者中的获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Functional polymorphisms (Ser49Gly and Arg389Gly) in ADRB1 have been associated with cardiovascular and β-blocker response outcomes. Herein we examined associations of these polymorphisms with major adverse cardiovascular events (MACE), with and without stratification by β-blocker treatment in patients with a history of stroke. METHODS: Nine hundred and twenty-six participants of the SPS3 trial's (Secondary Prevention of Small Subcortical Strokes) genetic substudy with hypertension were included. MACE included stroke, myocardial infarction, and all-cause death. Kaplan-Meier and multivariable Cox regression analyses were used. Because the primary component of MACE was ischemic stroke, we tested the association of Ser49Gly with ischemic stroke among 41 475 individuals of European and African ancestry in the NINDS (National Institute of Neurological Disorders and Stroke) SiGN (Stroke Genetics Network). RESULTS: MACE was higher in carriers of the Gly49 allele than in those with the Ser49Ser genotype (10.5% versus 5.4%, log-rank P=0.005). Gly49 carrier status was associated with MACE (hazard ratio, 1.62; 95% confidence interval, 1.00-2.68) and ischemic stroke (hazard ratio, 1.81; 95% confidence interval, 1.01-3.23) in SPS3 and with small artery ischemic stroke (odds ratio, 1.14; 95% confidence interval, 1.03-1.26) in SiGN. In SPS3, β-blocker-treated Gly49 carriers had increased MACE versus non-β-blocker-treated individuals and noncarriers (hazard ratio, 2.03; 95% confidence interval, 1.20-3.45). No associations were observed with the Arg389Gly polymorphism. CONCLUSION: Among individuals with previous small artery ischemic stroke, the ADRB1 Gly49 polymorphism was associated with MACE, particularly small artery ischemic stroke, a risk that may be increased among β-blocker-treated individuals. Further research is needed to define β-blocker benefit among ischemic stroke patients by ADRB1 genotype. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00059306.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Magvanjav O, McDonough CW, Gong Y, et al. Pharmacogenetic Associations of β1-Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes). Stroke. 2017. PMID: 28351962. doi:10.1161/STROKEAHA.116.015936

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。